scholarly journals A Two-Factor Model Better Explains Heterogeneity in Negative Symptoms: Evidence from the Positive and Negative Syndrome Scale

2016 ◽  
Vol 7 ◽  
Author(s):  
Seon-Kyeong Jang ◽  
Hye-Im Choi ◽  
Soohyun Park ◽  
Eunju Jaekal ◽  
Ga-Young Lee ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Factor Model ◽  
Syndrome Scale ◽  
Negative Syndrome

scholarly journals Large-Scale Evaluation of the Positive and Negative Syndrome Scale (PANSS) Symptom Architecture in Schizophrenia

2020 ◽  
Author(s):  
Keane Lim ◽  
Oon-Him Peh ◽  
Zixu Yang ◽  
Gurpreet Rekhi ◽  
Attilio Rapisarda ◽  
...  
Keyword(s):  
Factor Structure ◽  
Large Scale ◽  
Negative Symptoms ◽  
Factor Model ◽  
Meta Analysis ◽  
Temporal Stability ◽  
Model Fit ◽  
Syndrome Scale ◽  
Ultra High Risk ◽  
Negative Syndrome

Although the Positive and Negative Syndrome Scale (PANSS) is widely utilized in schizophrenia research, variability in specific item loading exist, hindering reproducibility and generalizability of findings across schizophrenia samples. We aim to establish a common metric PANSS factor structure from a large multi-ethnic sample and validate it against a meta-analysis of existing PANSS models. Schizophrenia participants (N = 3511) included in the current study were part of the Singapore Translational and Clinical Research Program (STCRP) and the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). Exploratory Factor Analysis (EFA) was conducted to identify the factor structure of PANSS and validated with a meta-analysis (N = 16,171) of existing PANSS models. Temporal stability of the PANSS model and generalizability to individuals at ultra-high risk (UHR) of psychosis were evaluated. A five-factor solution best fit the PANSS data. These were the i) Positive, ii) Negative, iii) Cognitive/disorganization, iv) Depression/anxiety and v) Hostility factors. Convergence of PANSS symptom architecture between EFA model and meta-analysis was observed. Modest longitudinal reliability was observed. The schizophrenia derived PANSS factor model fit the UHR population, but not vice versa. We found that two other domains, Social Amotivation (SA) and Diminished Expression (DE), were nested within the negative symptoms factor. Here, we report one of the largest transethnic factorial structures of PANSS symptom domains (N = 19,682). Evidence reported here serves as crucial consolidation of a common metric PANSS that could aid in furthering our understanding of schizophrenia.

The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model

2006 ◽  
Vol 85 (1-3) ◽  
pp. 280-287 ◽  
Author(s):  
M VANDERGAAG ◽  
T HOFFMAN ◽  
M REMIJSEN ◽  
R HIJMAN ◽  
L DEHAAN ◽  
...  
Keyword(s):  
Cross Validation ◽  
Factor Model ◽  
Five Factor Model ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Fold Cross Validation

Amendment of traditional assessment measures for the negative symptoms of schizophrenia

2018 ◽  
Vol 49 ◽  
pp. 50-55 ◽  
Author(s):  
Aida Farreny ◽  
Judith Usall ◽  
Jorge Cuevas-Esteban ◽  
Susana Ochoa ◽  
Gildas Brébion
Keyword(s):  
Verbal Memory ◽  
Regression Models ◽  
Negative Symptoms ◽  
Linear Regression Models ◽  
Illness Duration ◽  
Traditional Assessment ◽  
Syndrome Scale ◽  
Assessment Measures ◽  
Negative Syndrome ◽  
The Relationship

AbstractSchizophrenia research based on traditional assessment measures for negative symptoms appears to be, to some extent, unreliable. The limitations of the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS) have been extensively acknowledged and should be taken into account. The aim of this study is to show how the PANSS and the SANS conflate negative symptoms and cognition and to offer alternatives for the limitations found.MethodsA sample of 117 participants with schizophrenia from two independent studies was retrospectively investigated. Linear regression models were computed to explore the effect of negative symptoms and illness duration as predictors of cognitive performance.ResultsFor the PANSS, the item “abstract thinking” accounted for the association between negative symptoms and cognition. For the SANS, the “attention” subscale predicted the performance in verbal memory, but illness duration emerged as a stronger predictor than negative symptoms for outcomes of processing speed, verbal and working memory.ConclusionUtilizing alternative models to the traditional PANSS and SANS formats, and accounting for illness duration, provide more precise evidence on the relationship between negative symptoms and cognition. Since these measures are still extensively utilized, we recommend adopting more rigorous approaches to avoid misleading results.

scholarly journals Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia

2012 ◽  
Vol 137 (1-3) ◽  
pp. 246-250 ◽  
Author(s):  
R.S. Wallwork ◽  
R. Fortgang ◽  
R. Hashimoto ◽  
D.R. Weinberger ◽  
D. Dickinson
Keyword(s):  
Factor Model ◽  
Five Factor Model ◽  
Syndrome Scale ◽  
Negative Syndrome

scholarly journals Brain-Derived Neurotropic Factor Serum Level and Severity Symptom of Bataknese Male Patients with Schizophrenia in North Sumatera, Indonesia

2019 ◽  
Vol 7 (12) ◽  
pp. 1957-1961
Author(s):  
Deasy Hendriati ◽  
Elemeida Effendy ◽  
Mustafa Mahfud Amin ◽  
Vita Camellia ◽  
Muhammad Surya Husada
Keyword(s):  
Serum Level ◽  
Negative Correlation ◽  
Symptom Severity ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Serum Levels ◽  
Cross Sectional ◽  
Syndrome Scale ◽  
Male Patients ◽  
Negative Syndrome

BACKGROUND: Schizophrenia is a severe mental disorder that is multi-causative and multi-factor, generally affecting about 1% of the population. The elevation level of brain-derived neurotrophic factor (BDNF) offers several protections from other neurodegenerative processes that occur in schizophrenia since this deficit of neurotrophic factors can contribute to changes in brain structure and function that underlie the schizophrenia psychopathology.AIM: To analyse the correlation between BDNF serum levels and symptom severity by using the Positive and Negative Syndrome Scale (PANSS) instrument in Bataknese male patients with schizophreniaMETHODS: This study was a correlative analytical study with a cross-sectional approach using the Positive and Negative Syndrome Scale (PANSS) instrument to assess symptom severity with 60 subjects of Bataknese male patients with chronic schizophrenia. Moreover, this research was conducted at the Psychiatric Hospital of Prof. Dr M. Ildrem Medan, Indonesia. BDNF serum was analysed with the Quantitative sandwich enzyme immunoassay technique by via Quantikine ELISA Human CXCL8/IL-8 HS. Also, the data analysis was performed through Spearman's correlative bivariate analytics using SPSS software.RESULTS: A negative correlation between the BDNF serum level and the negative scale PANSS score in men with schizophrenia (r = -0.820, p < 0.001) was found. Moreover, there is a negative correlation between BDNF serum levels and PANSS total scores in men with schizophrenia (r = -0.648, p < 0.001)CONCLUSION: BDNF serum level in Bataknese male patients with schizophrenia has a relationship that affects the severity of symptoms in schizophrenic patients, especially for negative symptoms.

scholarly journals Socio Demographic Profile and Risperidone Response in New Versus Old Schizophrenia Patients

2020 ◽  
Vol 18 (1) ◽  
pp. 82-85
Author(s):  
Mohan Belbase ◽  
Jyoti Adhikari
Keyword(s):  
Negative Symptoms ◽  
Total Duration ◽  
P Value ◽  
Base Line ◽  
Age Group ◽  
Old Patients ◽  
Syndrome Scale ◽  
Significant Difference ◽  
The Mean ◽  
Negative Syndrome

Introduction: Schizophrenia is a mental disorder characterized with disorganized thinking, perception, expression of reality with significant social and occupational dysfunction. Two groups of drugs are in recent use namely first generation (typicals) and second generation (atypical) antipsychotics. Risperidone is a broad spectrum antipsychotic and has a role as a first-line agent for first break, mild to moderately ill patients and for severely ill treatment–refractory patients. Aims: This article tries to compare the risperidone response in newly diagnosed schizophrenia patients versus old patients already on some antipsychotics other than risperidone. Methods: This is an experimental intervention study of patients attending to psychiatry OPD and indoor in Nepalgunj Medical College, Kohalpur. Total 40 patients (27 new and 13 old) were selected and sample was collected in one year from January 2018 till December 2018. Positive and negative syndrome scale questionnaire was used to record the positive and negative symptoms of schizophrenia on baseline (week 0). Patients were followed up on week 4 and week 8 and the same positive and negative syndrome scale questionnaire was applied to record the improvement. Risperidone was given in therapeutic dose (4-8mg) on the basis of symptoms and improvement. Results: The study subjects were divided into new N=27 (17 male and 10 female) and old N=13 (7 male and 6 female). Maximum number of schizophrenia cases were in age group 15-25 and 35-44 years comprising 30 % in each group. Mean total duration of illness in new group was 23.89 ± 29.51 months (median being 12.0 months) while in old group it was 123.69 ± 83.34 months (median being 96.0 months) with significant difference between two groups (p= <0.001).The mean risperidone dose in milligram on base line (week 0) was 4.15 ±  0.55 for old group while it was 4.04 ± 0.52 for new group. On week 4, the mean dose for old group was 5.08 ± 0.95 while for the new group it was 4.81 ± 1.08. On week 8, the dose for old group was 6.08 ± 1.32 while it was 5.15 ± 1.35 for new group. There was a significant difference in the drug dose on week 8 between old group and new group with p value of 0.047 (statistically significant).  Conclusion: Our study suggests that schizophrenia is found in most productive age group. Risperidone is  effective in both new and old schizophrenia patients however old patients need higher dose of risperidone than new patients.

scholarly journals Symptom Outcome 1 Year after Admission to an Early Psychosis Program

2003 ◽  
Vol 48 (3) ◽  
pp. 204-207 ◽  
Author(s):  
Jean Addington ◽  
Erin Leriger ◽  
Donald Addington
Keyword(s):  
Negative Symptoms ◽  
Depression Scale ◽  
Early Psychosis ◽  
First Episode ◽  
First Year ◽  
Positive Symptoms ◽  
Syndrome Scale ◽  
Assessment Measures ◽  
Symptom Outcome ◽  
Negative Syndrome

Objective: To determine the change in positive, negative, and depressive symptoms after 1 year in an early psychosis program. Method: One hundred and eighty subjects were included from the first 257 admissions for a first episode of psychosis to a comprehensive early psychosis program. Most had a diagnosis of schizophrenia or schizophreniform disorder. Subjects were assessed on admission to the program and at 3, 6, and 12 months after admission. All 180 subjects completed the 1-year assessment. Assessment measures included the Positive and Negative Syndrome Scale and the Calgary Depression Scale for Schizophrenia. Results: There was a clinically and statistically significant improvement in positive symptoms by 3 months, depression increased at 3 months but significantly improved by 12 months, and negative symptoms changed little over the first year. Conclusions: The differential changes in symptoms in the first year after admission have implications for treatment.

Sign in / Sign up

Export Citation Format

Share Document